<DOC>
	<DOCNO>NCT03031938</DOCNO>
	<brief_summary>A4091065 multicenter , prospective , cohort study enhance physical neurodevelopmental surveillance characterize outcome related development infant age 15 month potentially expose tanezumab , placebo comparator via maternal exposure utero tanezumb study .</brief_summary>
	<brief_title>Protocol Monitor Neurological Development Infants With Exposure Utero From Birth 15 Months Tanezumab Clinical Studies</brief_title>
	<detailed_description>A4091065 long term observational follow study subject tanezumab interventional study A4091056 , A4091057 , A4091058 , A4091059 , A4091061 A4091063</detailed_description>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<criteria>Subject infant born mother expose study drug tanezumab clinical study . The infant 's mother ( tanezumab clinical study participant ) must review , agree sign inform consent document explain detail perinatal post natal follow . Where local regulation mandate , male parent would also review sign informed consent . Parents legal guardian must willing able comply schedule visit study procedure . There exclusion criterion participate study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>36 Months</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Exposure utero tanezumab program</keyword>
</DOC>